Brought to you by 
EluSys, US Army develop drugs against biowarfare agents
08 Nov 2000
Executive Summary
EluSys Therapeutics (antibody technology) and the US Army Medical Research Institute of Infectious Diseases (USAMRIID) will develop drugs to prevent disease and treat people exposed to anthrax and other biowarfare chemicals.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Large Molecule
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
EluSys, US Army develop drugs against biowarfare agents
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice